Elcatonin raises levels of vasoactive intestinal peptide in human plasma.
Elcatonin, used for treatment of hypercalcaemia, Paget's disease and osteoporosis, causes flushing of the face and hands. To determine whether this was because of increased levels of vasoactive intestinal peptide, which is known to induce vasodilation, the effect of elcatonin on the plasma levels of vasoactive intestinal peptide was studied in five healthy volunteers. After a single intramuscular administration of elcatonin (20 int units), peak plasma elcatonin levels (approx. 30 pg mL-1) were achieved 30 min after injection. Plasma vasoactive intestinal peptide concentrations rose similarly with peak levels of about 17 pg mL-1 after 30 min. Side-effects such as cutaneous flushing (most obvious in the face and hands) occurred to an extent dependent on the amount of elcatonin administered, and declined over 45 min in parallel with the fate of plasma vasoactive intestinal peptide. The side-effects of elcatonin, especially cutaneous flushing, seem to be closely connected with vasoactive intestinal peptide.
Takeyama
M
M
Department of Clinical Pharmacy, Oita Medical University, Japan.
Ikawa
K
K
Nagano
T
T
Mori
K
K
D000328:Adult; D002116:Calcitonin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007124:Immunoenzyme Techniques; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D014660:Vasoactive Intestinal Peptide / Q000097:blood*
D014660:Vasoactive Intestinal Peptide; D002116:Calcitonin; C012755:elcatonin